$ENTX SEC Filings

Filed On	Filing
27 Oct 2026	8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Regulation FD Disclosure Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
14 Oct 2026	Proxy statement: special meeting on November 24, 2026
06 Oct 2026	8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Regulation FD Disclosure Former Gilead and Amgen executive joins Entera with over 35 years of experience advancing and commercializing impactful and blockbuster therapies
23 Sep 2026	PRE 14A
28 Aug 2026	EFFECT
28 Aug 2026	424B3
21 Aug 2026	Form 3: Camisasca Riccardo Paolo, Chief Medical Officer No securities owned
21 Aug 2026	S-3
18 Aug 2026	8-K: Regulation FD Disclosure; Other Events
12 Aug 2026	D
07 Aug 2026	Form 4: Rubin Steven D, Director Received 19,117 shares as a grant or award · Granted 76,773 Stock Option (right to buy)
07 Aug 2026	Form 4: Malca Yonatan, Director Received 22,815 shares as a grant or award
07 Aug 2026	Form 4: Taitel Haya, Director Received 20,790 shares as a grant or award
07 Aug 2026	Form 4: Ellis Sean, Director Received 20,034 shares as a grant or award · Granted 40,000 Stock Option (right to buy)
07 Aug 2026	Form 4: Yaacov-Garbeli Dana, Chief Financial Officer Granted 140,000 Stock Option (right to buy)
07 Aug 2026	Form 4: Galitzer Hillel, Chief Operating Officer Granted 200,000 Stock Option (right to buy)
07 Aug 2026	Form 4: Burshtein Gregory, Chief of R&D Granted 180,000 Stock Option (right to buy)
07 Aug 2026	Form 4: Toledano Miranda Jayne, Director Granted 700,000 Stock Option (right to buy)
07 Aug 2026	Form 4: Germano Geno J, Director Received 25,014 shares as a grant or award · Granted 93,014 Stock Option (right to buy)
07 Aug 2026	S-8

Comments